Matches in DBpedia 2014 for { <http://dbpedia.org/resource/Conatumumab> ?p ?o. }
Showing items 1 to 39 of
39
with 100 items per page.
- Conatumumab abstract "Conatumumab (originally AMG 655) is a monoclonal antibody developed for the treatment of cancer. it is a fully human monoclonal agonist antibody directed against the extracellular domain of human TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) receptor 2 (TR-2, death receptor 5) with potential antineoplastic activity. Conatumumab mimics the activity of native TRAIL, binding to and activating TR-2, thereby activating caspase cascades and inducing tumor cell apoptosis. TR-2 is expressed by a variety of solid tumors and cancers of hematopoietic origin.The drug was developed by Amgen Inc.".
- Conatumumab atcPrefix "none".
- Conatumumab casNumber "896731-82-1".
- Conatumumab fdaUniiCode "1P48L61KM0".
- Conatumumab wikiPageID "19840808".
- Conatumumab wikiPageRevisionID "545471551".
- Conatumumab atcPrefix "none".
- Conatumumab c "6466".
- Conatumumab casNumber "896731".
- Conatumumab chemspiderid "NA".
- Conatumumab h "10006".
- Conatumumab hasPhotoCollection Conatumumab.
- Conatumumab kegg "D09329".
- Conatumumab mabType "mab".
- Conatumumab molecularWeight "145.65".
- Conatumumab n "1730".
- Conatumumab o "2024".
- Conatumumab s "40".
- Conatumumab source "u".
- Conatumumab synonyms "anti-TRAIL receptor 2 monoclonal antibody, AMG 655".
- Conatumumab target TNFRSF10B.
- Conatumumab type "mab".
- Conatumumab unii "1".
- Conatumumab verifiedfields "changed".
- Conatumumab verifiedrevid "460106777".
- Conatumumab subject Category:Amgen.
- Conatumumab type Drug.
- Conatumumab type DrugProduct.
- Conatumumab type FunctionalSubstance.
- Conatumumab comment "Conatumumab (originally AMG 655) is a monoclonal antibody developed for the treatment of cancer. it is a fully human monoclonal agonist antibody directed against the extracellular domain of human TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) receptor 2 (TR-2, death receptor 5) with potential antineoplastic activity. Conatumumab mimics the activity of native TRAIL, binding to and activating TR-2, thereby activating caspase cascades and inducing tumor cell apoptosis.".
- Conatumumab label "Conatumumab".
- Conatumumab label "Conatumumab".
- Conatumumab label "كوناتوموماب".
- Conatumumab sameAs Conatumumab.
- Conatumumab sameAs m.04q6qq6.
- Conatumumab sameAs Q3685951.
- Conatumumab sameAs Q3685951.
- Conatumumab wasDerivedFrom Conatumumab?oldid=545471551.
- Conatumumab isPrimaryTopicOf Conatumumab.